These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

516 related articles for article (PubMed ID: 33378989)

  • 1. Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size.
    Zhao H; Zhu Q; Zhang C; Li J; Wei M; Qin Y; Chen G; Wang K; Yu J; Wu Z; Chen X; Wang G
    Biomed Pharmacother; 2021 Jan; 133():110825. PubMed ID: 33378989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial.
    Bosaeed M; Mahmoud E; Hussein M; Alharbi A; Alsaedy A; Alothman A; Aljeraisy M; Alqahtani H; Nashabat M; Almutairi B; Almaghaslah M; Aldibasi O; AlJohani S; Bouchama A; Arabi Y; Alaskar A
    Trials; 2020 Oct; 21(1):904. PubMed ID: 33129363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Favipiravir in the treatment of patients with SARS-CoV-2 RNA recurrent positive after discharge: A multicenter, open-label, randomized trial.
    Zhao H; Zhang C; Zhu Q; Chen X; Chen G; Sun W; Xiao Z; Du W; Yao J; Li G; Ji Y; Li N; Jiang Y; Wang Y; Zeng Q; Li W; Gong B; Chang X; Zhu F; Jiang X; Li J; Wu Z; Liu Y; Peng P; Wang G
    Int Immunopharmacol; 2021 Aug; 97():107702. PubMed ID: 33930706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study.
    Dabbous HM; Abd-Elsalam S; El-Sayed MH; Sherief AF; Ebeid FFS; El Ghafar MSA; Soliman S; Elbahnasawy M; Badawi R; Tageldin MA
    Arch Virol; 2021 Mar; 166(3):949-954. PubMed ID: 33492523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Mechanism and Clinical Outcome of patients with Corona Virus Disease 2019 Whose Nucleic Acid Test has changed from negative to positive, and the therapeutic efficacy of Favipiravir: A structured summary of a study protocol for a randomised controlled trial.
    Li J; Zhang C; Wu Z; Wang G; Zhao H
    Trials; 2020 Jun; 21(1):488. PubMed ID: 32503657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia.
    Solaymani-Dodaran M; Ghanei M; Bagheri M; Qazvini A; Vahedi E; Hassan Saadat S; Amin Setarehdan S; Ansarifar A; Biganeh H; Mohazzab A; Khalili D; Hosein Ghazale A; Reza Heidari M; Taheri A; Khoramdad M; Mahdi Asadi M; Nazemieh M; Varshochi M; Abbasian S; Bakhtiari A; Mosaed R; Hosseini-Shokouh SJ; Shahrokhi M; Yassin Z; Ali Zohal M; Qaraati M; Rastgoo N; Sami R; Javad Eslami M; Asghari A; Namazi M; Ziaie S; Jafari-Moghaddam R; Kalantari S; Memarian M; Khodadadi J; Hossein Afshari M; Momen-Heravi M; Behzadseresht N; Reza Mobayen A; Mozafari A; Movasaghi F; Haddadzadeh Shoushtari M; Moazen J
    Int Immunopharmacol; 2021 Jun; 95():107522. PubMed ID: 33735712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The praise of uncertainty: a systematic living review to evaluate the efficacy and safety of drug treatments for patients with covid-19.].
    Cruciani F; Amato L; De Crescenzo F; Mitrova Z; Saulle R; Vecchi S; Davoli M
    Recenti Prog Med; 2021 Mar; 112(3):195-206. PubMed ID: 33687358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molnupiravir versus favipiravir in at-risk outpatients with COVID-19: A randomized controlled trial in Thailand.
    Salvadori N; Jourdain G; Krittayaphong R; Siripongboonsitti T; Kongsaengdao S; Atipornwanich K; Sakulkonkij P; Angkasekwinai N; Sirijatuphat R; Chusri S; Mekavuthikul T; Apisarnthanarak A; Srichatrapimuk S; Sungkanuparph S; Kirdlarp S; Phongnarudech T; Sangsawang S; Napinkul P; Achalapong J; Khusuwan S; Pratipanawat P; Nookeu P; Danpipat N; Leethong P; Hanvoravongchai P; Sukrakanchana PO; Auewarakul P
    Int J Infect Dis; 2024 Jun; 143():107021. PubMed ID: 38561040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glasgow Early Treatment Arm Favirpiravir (GETAFIX) for adults with early stage COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Hanna CR; Blyth KG; Burley G; Carmichael S; Evans C; Hinsley S; Khadra I; Khoo S; Lewsley LA; Jones RR; Sharma R; Taladriz-Sender A; Thomson EC; Scott JT
    Trials; 2020 Nov; 21(1):935. PubMed ID: 33213530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A case of successful treatment of severe COVID-19 pneumonia with favipiravir and tocilizumab in post-kidney transplant recipient.
    Thammathiwat T; Tungsanga S; Tiankanon K; Torvorapanit P; Chumpangern W; Udomkarnjananun S; Avihingsanon Y; Sriprasart T; Srisawat N; Jutivorakool K; Paitoonpong L; Putcharoen O; Townamchai N
    Transpl Infect Dis; 2021 Feb; 23(1):e13388. PubMed ID: 32585765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19.
    Doi Y; Hibino M; Hase R; Yamamoto M; Kasamatsu Y; Hirose M; Mutoh Y; Homma Y; Terada M; Ogawa T; Kashizaki F; Yokoyama T; Koba H; Kasahara H; Yokota K; Kato H; Yoshida J; Kita T; Kato Y; Kamio T; Kodama N; Uchida Y; Ikeda N; Shinoda M; Nakagawa A; Nakatsumi H; Horiguchi T; Iwata M; Matsuyama A; Banno S; Koseki T; Teramachi M; Miyata M; Tajima S; Maeki T; Nakayama E; Taniguchi S; Lim CK; Saijo M; Imai T; Yoshida H; Kabata D; Shintani A; Yuzawa Y; Kondo M
    Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32958718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial.
    Brown LK; Freemantle N; Breuer J; Dehbi HM; Chowdhury K; Jones G; Ikeji F; Ndoutoumou A; Santhirakumar K; Longley N; Checkley AM; Standing JF; Lowe DM
    Trials; 2021 Mar; 22(1):193. PubMed ID: 33685502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Favipiravir-induced fever in coronavirus disease 2019: A report of two cases.
    Takoi H; Togashi Y; Fujimori D; Kaizuka H; Otsuki S; Wada T; Takeuchi Y; Abe S
    Int J Infect Dis; 2020 Dec; 101():188-190. PubMed ID: 32992014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis.
    Manabe T; Kambayashi D; Akatsu H; Kudo K
    BMC Infect Dis; 2021 May; 21(1):489. PubMed ID: 34044777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of favipiravir in COVID-19: a live systematic review.
    Özlüşen B; Kozan Ş; Akcan RE; Kalender M; Yaprak D; Peltek İB; Keske Ş; Gönen M; Ergönül Ö
    Eur J Clin Microbiol Infect Dis; 2021 Dec; 40(12):2575-2583. PubMed ID: 34347191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An adaptive randomised placebo controlled phase II trial of antivirals for COVID-19 infection (VIRCO): A structured summary of a study protocol for a randomised controlled trial.
    McMahon JH; Lau JSY; Roney J; Rogers BA; Trubiano J; Sasadeusz J; Molton JS; Gardiner B; Lee SJ; Hoy JF; Cheng A; Peleg AY
    Trials; 2020 Oct; 21(1):847. PubMed ID: 33050947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the efficacy and safety of favipiravir and interferon compared to lopinavir/ritonavir and interferon in moderately ill patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial.
    Hassaniazad M; Bazram A; Hassanipour S; Fathalipour M
    Trials; 2020 Oct; 21(1):886. PubMed ID: 33109246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Promising effects of tocilizumab in COVID-19: A non-controlled, prospective clinical trial.
    Dastan F; Saffaei A; Haseli S; Marjani M; Moniri A; Abtahian Z; Abedini A; Kiani A; Seifi S; Jammati H; Hashemian SMR; Pourabdollah Toutkaboni M; Eslaminejad A; Heshmatnia J; Sadeghi M; Nadji SA; Dastan A; Baghaei P; Varahram M; Yousefian S; Salamzadeh J; Tabarsi P
    Int Immunopharmacol; 2020 Nov; 88():106869. PubMed ID: 32889241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The comparison of favipiravir and lopinavir/ritonavir combination in COVID-19 treatment.
    Çınarka H; Günlüoğlu G; Çörtük M; Yurt S; Kıyık M; Koşar F; Tanrıverdi E; Arslan MA; Baydili KN; Koç AS; Altın S; Çetinkaya E
    Turk J Med Sci; 2021 Aug; 51(4):1624-1630. PubMed ID: 33726482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia.
    Khamis F; Al Naabi H; Al Lawati A; Ambusaidi Z; Al Sharji M; Al Barwani U; Pandak N; Al Balushi Z; Al Bahrani M; Al Salmi I; Al-Zakwani I
    Int J Infect Dis; 2021 Jan; 102():538-543. PubMed ID: 33181328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.